Patents by Inventor Meiwei Wang

Meiwei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240425999
    Abstract: An electrolysis device, electrolysis system, and electrolysis method for alternating current induction power supply are provided. The electrolysis device includes at least one group of magnetic circuits and an electrolytic cell. The magnetic circuit has a magnetic core on which an electromagnetic coil is wound, the magnetic core being provided outside the electrolytic cell. The magnetic circuits are used for using an alternating current power source to generate a rotating magnetic field surrounding the electrolytic cell, the rotating magnetic field acting on an electrolyte in the electrolytic cell to generate an induction direct current, such that the electrolyte is electrolyzed. According to the electrolysis device, the electrolytic cell generates the induction direct current directly by means of an alternating current, such that alternating current and direct current conversion links are reduced, and energy loss caused by energy conversion is reduced.
    Type: Application
    Filed: October 25, 2022
    Publication date: December 26, 2024
    Inventors: Zhentang SHI, Meiwei WANG, Jun LI, Guanlin WU, Linan TAO, Jin SUN
  • Patent number: 11976054
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 7, 2024
    Assignee: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Publication number: 20230227482
    Abstract: Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: July 20, 2023
    Inventors: Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230165867
    Abstract: The present application relates to imidazolidinone derivatives and medical use thereof, and in particular relates to pyrimidine derivatives represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or co-crystals thereof, a pharmaceutical composition comprising the same, and use of the compound or pharmaceutical composition according to the present application in the manufacture of a medicament for treatment of cancer.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 1, 2023
    Inventors: Yonggang WEI, Xuezhen XU, Hongzhu CHU, Lvxue HE, Feiquan LEI, Jie YAN, Yang HE, Meiwei WANG, Guizhuan SU, Bing LIU, Yi SUN
  • Publication number: 20230059087
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: February 23, 2023
    Inventors: Xibing ZHOU, Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230002425
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
    Type: Application
    Filed: January 7, 2021
    Publication date: January 5, 2023
    Inventors: Xuezhen XU, Jing ZHANG, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20220411392
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 29, 2022
    Applicant: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Publication number: 20220402920
    Abstract: The present invention relates to a purine derivative and use thereof in medicine, and in particular to a pyrimidine derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, prodrug, deuteride, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of preparation of a DNA-PK inhibitor, wherein the substituents in general formula (I) are defined in the same way as in the specification
    Type: Application
    Filed: December 30, 2020
    Publication date: December 22, 2022
    Inventors: Yonggang Wei, Xuezhen Xu, Hongzhu Chu, Lvxue He, Xiangyu Meng, Meiwei Wang, Guizhuan Su, Bing Liu, Yi Sun